Prediction of , index 1596
Prospective Prediction
- Prediction Index
- 1596
- Prediction Date
- Commercial Prediction
- FAILURE (commercially insufficient additive clinical benefit of obicetrapib in MACE with significantly increased toxicity-driven mortality; The MACE-based clinical benefit of obicetrapib + ezetimibe + SoC is inferior to that of SoC + ezetimibe or SoC alone)
- Technical Prediction
- partial SUCCESS (statistically maybe significant yet weak additive clinical benefit of obicetrapib in LDL-C reduction)
Readout of
Prediction Validation
- Readout Date
- Prediction To Readout
- 192 days in advance
- Readout Data Interpretation
- obicetrapib + ezetimibe + SoC achieved 48.6% LDL-C reduction at day 84; which is superior to ezetimibe + SoC or SoC alone (yet weaker than 54-59% reduction as the market consensus for strong efficacy); obicetrapib achieved 7% TEAE; which is inferior to ezetimibe + SoC (3%) or SoC alone (4%)
- Press Release
- Press Release (finance.yahoo.com)
Prediction Result
- Prediction Accuracy
- Correct Prediction
- Clinical Benefit Conclusion
- statistically significant yet weak and commercially TBD (no MACE data available)
- Prediction Classification
- True Positive (TP)